These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 11773572

  • 1. Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?
    Williams RV, Wilke VM, Tani LY, Minich LL.
    Pediatrics; 2002 Jan; 109(1):E4. PubMed ID: 11773572
    [Abstract] [Full Text] [Related]

  • 2. Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease.
    Etheridge SP, Tani LY, Minich LL, Revenaugh JR.
    Cathet Cardiovasc Diagn; 1998 Nov; 45(3):264-8. PubMed ID: 9829884
    [Abstract] [Full Text] [Related]

  • 3. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease?
    McCandless RT, Minich LL, Tani LY, Williams RV.
    Am J Cardiol; 2010 Jun 01; 105(11):1625-8. PubMed ID: 20494673
    [Abstract] [Full Text] [Related]

  • 4. Management of coronary artery aneurysms using abciximab in children with Kawasaki disease.
    Bachlava E, Loukopoulou S, Karanasios E, Chrousos G, Michos A.
    Int J Cardiol; 2016 Oct 01; 220():65-9. PubMed ID: 27372045
    [Abstract] [Full Text] [Related]

  • 5. Frequency and efficacy of glycoprotein IIb/IIIa therapy for treatment of threatened or acute vessel closure in 1332 patients undergoing percutaneous transluminal coronary angioplasty.
    Haase KK, Mahrholdt H, Schröder S, Baumbach A, Oberhoff M, Herdeg C, Karsch KR.
    Am Heart J; 1999 Feb 01; 137(2):234-40. PubMed ID: 9924156
    [Abstract] [Full Text] [Related]

  • 6. [Kawasaki disease in children--9 years experience].
    Kowalczyk M, Kawalec W, Daszkowska-York J, Turska-Kmieć A, Brzezińska-Rajszys G, Sobielarska D, Ziółkowska L, Kościesza A, Jagiełłowicz D, Mirecka-Rola A.
    Med Wieku Rozwoj; 2005 Feb 01; 9(2):179-93. PubMed ID: 16085959
    [Abstract] [Full Text] [Related]

  • 7. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.
    N Engl J Med; 1999 Jul 29; 341(5):319-27. PubMed ID: 10423466
    [Abstract] [Full Text] [Related]

  • 8. A child with Kawasaki disease who survived after rupture of a coronary artery aneurysm.
    Mok GC, Sung RY, Yam MC, Arifi AA, Lam WW, Fok TF.
    Eur J Pediatr; 2003 Sep 29; 162(9):634-6. PubMed ID: 12811552
    [No Abstract] [Full Text] [Related]

  • 9. Extensive coronary aneurysms with thrombosis in resistant Kawasaki disease.
    Sivakumar K, Pavithran S.
    Pediatr Cardiol; 2013 Feb 29; 34(2):444-6. PubMed ID: 22427313
    [Abstract] [Full Text] [Related]

  • 10. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
    Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, Nekolla SG, Seyfarth M, Martinoff S, Markwardt C, Clermont G, Gerbig HW, Leiss J, Schwaiger M, Schömig A, Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators.
    JAMA; 2004 Feb 25; 291(8):947-54. PubMed ID: 14982910
    [Abstract] [Full Text] [Related]

  • 11. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T, McGavin JK, Goa KL.
    Am J Cardiovasc Drugs; 2003 Feb 25; 3(5):381-6. PubMed ID: 14728074
    [Abstract] [Full Text] [Related]

  • 12. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ, Van der Planken MG, Bosmans JM, Michiels JJ, Vertessen F, Van Der Goten P, Wuyts FL, Vrints CJ.
    Eur Heart J; 2005 Mar 25; 26(6):567-75. PubMed ID: 15618034
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Giant coronary thrombus as a complication of Kawasaki disease].
    Kádár K, Piskóthy A, Bendig L.
    Orv Hetil; 1993 Oct 31; 134(44):2431-3. PubMed ID: 8233462
    [Abstract] [Full Text] [Related]

  • 15. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T, McGavin JK, Goa KL.
    Drugs; 2003 Oct 31; 63(11):1121-63. PubMed ID: 12749745
    [Abstract] [Full Text] [Related]

  • 16. Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
    Jone PN, Tapia D, Davidson J, Fagan TE, Browne L, Ing RJ, Kay J.
    Semin Cardiothorac Vasc Anesth; 2015 Sep 31; 19(3):255-9. PubMed ID: 25700695
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M, Gruberg L, Hammerman H, Aronson D, Halabi M, Goldberg A, Grenadier E, Boulus M, Markiewicz W, Beyar R.
    J Invasive Cardiol; 2003 Jun 31; 15(6):319-23. PubMed ID: 12777670
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?].
    Hernández García JM, Domínguez Franco A, Jiménez-Navarro MF, Alonso Briales JH, Curiel Balsera E, Gómez Doblas JJ, De Teresa Galván E.
    Rev Esp Cardiol; 2002 Aug 31; 55(8):810-5. PubMed ID: 12199976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.